Kathy Castor: “I thank the ranking member for yielding me this time. Madam Speaker, there are a number of reasons why H.R. 6190 is poor…”

“I thank the ranking member for yielding me this time. Madam Speaker, there are a number of reasons why H.R. 6190 is poor public policy, but I'd like to focus on just one, and that is the unfair advantage that this bill will grant to a single business to the detriment of other businesses and manufacturers. And, in fact, the Congress has received a letter from the International Pharmaceutical Aerosol Consortium: On behalf of the International Pharmaceutical Aerosol Consortium--an association of companies that manufacture medicines for the treatment of respiratory illnesses, such as asthma and chronic obstructive pulmonary disease--I am writing to you today in opposition to H.R. 6190. IPAC's members include AstraZeneca, GlaxoSmithKline, and a number of other manufacturers. They say that they strongly oppose efforts within the House of Representatives to lift the December 31, 2011, ban on the sale of CFC-based epinephrine Primatene Mist because such drastic reversal in settled law will be, one, unnecessary to protect the public health of asthma patients; and, two, it's contrary to the United States' important and long-standing commitment to international treaties. They point out that this has been ongoing for two decades. The companies involved in international manufacture, national manufacturers, have known about this for a long time.…”